Claims

- 1. (Previously Presented) An isolated polypeptide comprising:
- (1) at least eight consecutive amino acids of amino acids 157-933 of SEQ ID NO: 1, wherein the isolated polypeptide is eight to ten amino acids in length and binds a Major Histocompatability Complex (MHC) molecule; or
 - (2) the amino acid sequence set forth as SEQ ID NO: 1.
 - 2. (Canceled).
 - 3. (Canceled).
- 4. (Currently Amended) The isolated polypeptide of claim 1, comprising the at the least eight consecutive amino acids of amino acids 157-933 of SEQ ID NO: 1, wherein the isolated polypeptide is eight to ten amino acids in length and binds an MHC molecule.
- 5. (Original) The isolated polypeptide of claim 1, comprising an amino acid sequence as set forth as SEQ ID NO: 1.
 - 6. (Canceled).
- 7. (Currently Amended) An isolated nucleic acid sequence polynucleotide comprising the nucleic acid sequence as set forth as SEQ ID NO: 2, or a degenerate variant thereof.
- 8. (Previously Presented) The isolated nucleic acid sequence of claim 7, operably linked to a promoter.
- 9. (Previously Presented) An expression vector comprising the nucleic acid sequence of claim 7.

- 10. (Previously Presented) An isolated host cell transfected with the nucleic acid sequence of claim 7.
- 11. (Previously Presented) The isolated_host cell of claim 10, wherein the host cell is a mammalian cell.
 - 12-20. (Canceled).
- 21. (Withdrawn and Currently Amended) A method for detecting a prostate eancer <u>cell</u> in a subject, comprising

detecting the expression of the polypeptide of claim 1 in a sample from the subject, wherein-an increase in the expression of the polypeptide as compared to a control indicates the presence of the prostate <u>cell</u> eancer.

- 22. (Withdrawn and Currently Amended) The method of claim 21, wherein detecting the expression of polypeptide comprises detecting a polypeptide having a consisting of the amino acid sequence set forth as SEQ ID NO: [[2]] 1 in the sample.
- 23. (Withdrawn) The method of claim 22, wherein detecting the expression of the polypeptide comprises

contacting the sample with an antibody that specifically binds the polypeptide for a sufficient amount of time to form an immune complex; and

detecting the presence of the immune complex.

24. (Currently Amended) A method for detecting <u>prostate cells a prostate cancer or prostate tissue</u> in a subject, comprising

detecting expression of the polynucleotide of claim 7 in a sample from the subject, wherein an increase in the expression of the polynucleotide as compared to a control indicates the presence of the <u>prostate cells</u> prostate cancer or the prostate tissue.

- 25. (Previously Presented) The method of claim 24, wherein detecting the expression of the polynucleotide comprises detecting mRNA in a Northern Blot analysis, an RNA Dot blot, or a reverse transcriptase polymerase chain reaction (RT-PCR) assay.
- 26. (Currently Amended) A method for producing an immune response to the against a cell expressing a polypeptide of claim 1 in a subject, the method comprising

administering to [[the]] <u>a</u> subject a therapeutically <u>an</u> effective amount of the polypeptide of claim 1, or a polynucleotide encoding the polypeptide,

thereby producing the immune response to the polypeptide.

- 27. (Canceled).
- 28. (Currently Amended) The method of claim 26, wherein the immune response [[is]] comprises production of antibodies a B cell response.
 - 29-38. (Canceled).
- 39. (Previously Presented) A composition comprising the polypeptide of claim 1 in a carrier.
 - 40-47. (Canceled).
 - 48. (Previously Presented) A fusion protein, comprising
- a) the polypeptide of claim 1, wherein the polypeptide consists of at least eight consecutive amino acids of amino acids 157-933 of SEQ ID NO: 1, wherein the isolated polypeptide is eight to ten amino acids in length and binds a Major Histocompatablity Complex (MHC) molecule; and
 - b) a heterologous polypeptide.
- 49. (Previously Presented) An isolated polynucleotide encoding the polypeptide of claim 47.

- 50. (Previously Presented) The isolated nucleic acid sequence of claim 49 operably linked to a promoter.
- 51. (Previously Presented) An expression vector comprising the nucleic acid sequence of claim 50.
- 52. (Previously Presented) An isolated host cell transfected with the nucleic acid sequence of claim 50.
- 53. (Previously Presented) The isolated host cell of claim 52, wherein the host cell is a mammalian cell.
- 54. (Currently Amended) The An isolated polypeptide of claim 1, consisting of the amino acid sequence set forth as amino acids 157-933 of SEQ ID NO: 1.
- 55. (Currently Amended) The An isolated polypeptide of claim 54, consisting of the amino acid sequence set forth as one of SEQ ID NO: 3-10.